Counterpoint: were industry-sponsored roflumilast trials appropriate? No
- PMID: 24798831
- PMCID: PMC4011655
- DOI: 10.1378/chest.14-0114
Counterpoint: were industry-sponsored roflumilast trials appropriate? No
Comment in
-
Rebuttal from Drs Suissa and Rabe.Chest. 2014 May;145(5):942-3. doi: 10.1378/chest.14-0113. Chest. 2014. PMID: 24798832 No abstract available.
-
Roflumilast in COPD.Chest. 2015 Jul;148(1):e31. doi: 10.1378/chest.15-0664. Chest. 2015. PMID: 26149563 No abstract available.
-
Response.Chest. 2015 Jul;148(1):e31-e32. doi: 10.1378/chest.15-0837. Chest. 2015. PMID: 26149564 Free PMC article. No abstract available.
Comment on
-
Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.Lancet. 2005 Aug 13-19;366(9485):563-71. doi: 10.1016/S0140-6736(05)67100-0. Lancet. 2005. PMID: 16099292 Clinical Trial.
-
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Lancet. 2009. PMID: 19716960 Clinical Trial.
-
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.Lancet. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6. Lancet. 2009. PMID: 19716961 Clinical Trial.
References
-
- Ioannidis JP. Mega-trials for blockbusters. JAMA. 2013;309(3):239-240 - PubMed
-
- Nycomed’s novel COPD therapy roflumilast receives FDA approval. WorldPharmaNews website. http://www.worldpharmanews.com/nycomed/1600-nycomeds-novel-copd-therapy-.... Accessed March 13, 2012
-
- Forest Laboratories management discusses Q3 2012 results-earnings call transcript 2012. Seeking Alpha website. http://seekingalpha.com/article/320088-forest-laboratories-management-di.... Accessed October 2, 2012
-
- Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563-571 - PubMed
-
- Bergmann JF. Roflumilast for chronic obstructive pulmonary disease. Lancet. 2005;366(9500):1845. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical